Tag Archives | News Releases

IntegenX Names Robert A. Schueren Chief Executive Officer

PLEASANTON, Calif. – April 17, 2013 – IntegenX Inc., a privately held company and leading developer of rapid human DNA identification technology, DNA sequencing library preparation systems, and DNA/RNA ambient temperature stability and storage products, today announced the appointment of Robert A. Schueren as Chief Executive Officer.

Robert A. Schueren has nearly 30 years of commercial and operational experience, and has held leadership positions in life science companies for more than two decades. Most recently, he was Vice President and General Manager, Genomics, for Agilent Technologies. Prior to joining Agilent in 2010, he was the Global Head of Clinical Biomarkers and Operations and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc., a company he joined in 2006. While at Genentech, Mr. Schueren held increasingly responsible positions including Senior Director, Development Sciences and Director Companion Diagnostics. Prior to Genentech, Mr. Schueren was the Executive Vice President and Chief Operating Officer of Arcturus Bioscience from 2003 to 2006. From 1997 to 2002, Mr. Schueren held leadership positions with Accumetrics. He also held commercial positions with Biosite Diagnostics and Gen-Probe, Inc.

“IntegenX is uniquely positioned to lead the revolution in how rapid DNA is applied—one that will transform law enforcement, intelligence and border control. For the first time, rapid DNA profiles will be included in the arsenal of actionable information used for human identification and to strengthen criminal and terrorist investigations.” said Mr. Schueren. “I am excited to participate in this new revolution and look forward to working with the IntegenX team as we drive the development of the significant new markets rapid DNA creates.”

Stevan Jovanovich, Ph.D., a founder and past President and CEO of IntegenX, will remain with the Company as Chief Technology Officer.

“We are delighted to have Bob join the company. His significant commercial and operations experience at companies such as Agilent and Genentech will prove invaluable as IntegenX commercializes its rapid human DNA identification system,” commented Dr. David Barker, Chairman of the Board of IntegenX. “The board is also very pleased that Stevan will assume the role of Chief Technology Officer, where he will continue to play a critical part in building the success of the Company.”

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-generation sequencing library preparation systems, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing and forensics, next generation sequencing, and biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented DNA and RNA reagents including GenTegra™ for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, PrepX, MOVe, GenTegra, GenPlate and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

 

###

 

Contact:

David V. Smith
Chief Operating Officer
IntegenX Inc.
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588
925.701.3400

IntegenX Teams with SAIC to Pursue Defense Threat Reduction Agency Contracts Using Rapid DNA Biometrics Capability

Fast DNA Analysis Yields Tactical Advantages in the Field

Pleasanton, CA — February 26, 2013 — IntegenX and Science Applications International Corporation (SAIC) announced today that they have signed a teaming agreement to pursue Defense Threat Reduction Agency (DTRA) Indefinite Delivery/Indefinite Quantity (ID/IQ) Awards supporting U.S. needs for detection of weapons of mass destruction. Support provided by IntegenX and SAIC will enable warfighters to complete their missions efficiently and effectively by supplying an integrated system that provides rapid DNA-based identification of biothreat agents.

Rapid DNA analysis is a transformative technology set to fundamentally change the way investigations are conducted by enabling the rapid and definitive identification of bioagents. Rapid DNA technology has the potential to help protect communities through quick detection of biothreat agents and to provide world class DNA identification capabilities to field forward personnel.

In 2012, IntegenX successfully participated in an invitation-only U.S. Department of Defense (DOD) exercise where its RapidHIT™ 200 Human DNA Identification System repeatedly delivered accurate human DNA profiles from swabs, bottles, cans, sputum, hair, saliva and blood. The RapidHIT 200 is a mobile, self-contained DNA identification system that automates and accelerates the process of producing standardized DNA profiles from samples in less than 90 minutes. The teaming agreement pairs SAIC’s biodefense capabilities with IntegenX’s rapid DNA technologies. IntegenX will leverage its RapidHIT System as part of the agreement and SAIC will integrate its software and biodefense capability with the RapidHIT to customize the system for detection of biothreats.

“The RapidHIT System will allow for rapid DNA analysis at the point of action, setting a new standard in the usage of DNA profiles to detect and identify bioagents down to the sub-species level in less than 90 minutes,” said Stevan Jovanovich, Ph.D., President and Chief Executive Officer of IntegenX. “Teaming with SAIC will give the U.S. government further access to IntegenX’s rapid DNA technology. SAIC has shown that they can integrate complex software and detection modalities for support of military biodefense applications.”

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-generation sequencing library preparation, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, proprietary PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented reagents for DNA and RNA preservation including GenTegra® for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples. For more information, please visit www.integenx.com.
IntegenX, the IntegenX logo, PrepX, MOVe, GenTegra, GenPlate and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

IntegenX Inc. Expands Global Footprint with Appointment of Middle East Distributor

RapidHIT™ 200 Human DNA Identification System helps law enforcement and security agencies generate DNA profiles on location in 90 minutes.

Pleasanton, CA USA and Dubai, UAE – February 19, 2013 – IntegenX Inc., creator and developer of the first commercially available system for rapid DNA identification — the RapidHIT™ 200 — announced today that it has signed an exclusive distribution agreement with Scientific Analytical Tools Trading, LLC (SAT), the leading provider of forensic equipment and laboratory design services to the Gulf Cooperation Council (GCC) countries in the Middle East. Under the terms of the agreement, SAT will lead all sales, marketing and service functions for the RapidHIT 200 Human Identification System in the United Arab Emirates, Oman, Kuwait, Bahrain, Qatar and Saudi Arabia.

Rapid DNA is a transformative technology that promises to fundamentally change the way DNA-based human identification is used by law enforcement and government security agencies. The RapidHIT 200 Human DNA Identification System reduces the time required for human identification by DNA analysis from days or weeks to just 90 minutes, and has already been deployed in the United States, Europe and the Middle East.

“The RapidHIT System is clearly revolutionizing the ability to rapidly and reliably generate human DNA profiles to help make our communities safer, and we are pleased to have been selected as the exclusive distributor of this ground-breaking technology in the GCC,” said Mr. Ehsan Ravari, of SAT. “We look forward to leveraging our deep understanding of this market, our technical capabilities and our strong presence across the region to accelerate the adoption of rapid DNA usage.”

“The RapidHIT System allows, for the first time, DNA analysis at the point of collection, setting a new standard in the usage of DNA profiles as an actionable biometric similar to fingerprints,” said Stevan Jovanovich, Ph.D., president and chief executive officer of IntegenX. “We have had tremendous interest from the international community, are actively working with local agencies to further expand the use of Rapid DNA and are pleased that SAT will be representing us in the GCC countries.”

About Scientific Analytical Tools (SAT)
SAT, based in U.A.E., since 2004 supplies, installs and services analytical laboratory Instrumentation. The company also designs and plans laboratory facilities for healthcare, educational, industrial and material sciences customers. SAT has focused on forensic laboratories becoming the primary supplier of forensic products for chemistry, toxicology, fingerprinting, photography, firearms analysis, immigration control, special task force outfitting and coast guard support to law enforcement in the GCC. For more information, please visit www.sat.ae.

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-generation sequencing library preparation, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, proprietary PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented reagents for DNA and RNA preservation including GenTegra® for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, PrepX, GenTegra, GenPlate and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

IntegenX Announces Issuance of Key Patent for Ambient Temperature Storage of DNA and RNA

PLEASANTON, CA – November 9, 2012 – IntegenX reported today that the USPTO has issued U.S. Patent # 8,283,165 to Mike Hogan, PhD, and GenVault Corporation, a subsidiary of IntegenX Inc. This is a fundamental patent covering formulations to create a dry state matrix for ambient temperature preservation of RNA and DNA. While significant advances in high-throughput sequencing have been made in recent years, technologies for sample storage and transport have not enjoyed the same breakthroughs. IntegenX provides GenTegra® DNA and GenTegra RNA as chemical matrices that protect samples from hydrolysis, oxidation and microbial destruction. The GenTegra products allow scientists to collect, transport and store their samples indefinitely and safely at ambient temperatures. Further, GenTegra has been shown to protect DNA and RNA at temperature extremes — from -80 °C to 76 °C — that might be encountered during unrefrigerated shipping.

“Since the acquisition of GenVault Corporation by IntegenX in 2011, we have continued to develop products to help customers ensure the integrity of their precious samples for forensics, next generation sequencing, cancer research and for biological investigation,” said Stevan Jovanovich, President and Chief Executive Officer of IntegenX. “IntegenX is delighted that the USPTO has recognized the novel and unique character of GenTegra in granting this key patent to Dr. Hogan and GenVault Corporation.”

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products.  IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented reagents for DNA and RNA preservation including GenTegra® for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples.  For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, PrepX, GenTegra and GenPlate are trademarks of IntegenX Inc.
All other names and trademarks are the property of their respective owners.

Contact:

Howard D. Goldstein
IntegenX Inc.
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588

925.701.3481

howardg@integenX.com

 

###

IntegenX Announces Rapid Directional mRNA Library Preparation Kit for Next Generation Sequencing (NGS)

PLEASANTON, CA – November 6, 2012 – IntegenX Inc. today announced the commercial introduction of the company’s directional messenger RNA (mRNA) kit for automated NGS library preparation on the Apollo 324™ System. Requiring just 500 picograms of mRNA starting material, the new kit speeds RNA-Seq analysis of a broad range of clinical samples including tissue collections, allowing for rapid, systematic, genetic exploration. The new product joins an expanding IntegenX offering of DNA, RNA, and ChIP-Seq kits for preparing sequencing libraries for analysis on popular NGS platforms from Illumina® (GA, HiSeq™ and MiSeq™), Life Technologies (Ion Proton™ and Ion Torrent PGM™), and Roche (GS Junior™, GS FLX™ and GS FLX+). The company made the announcement at the 2012 annual meeting of the American Society of Human Genetics in San Francisco, California.

The new mRNA kit product announcement follows the recent formation of a Sequencing Business Unit at IntegenX to handle fast-growing demand for the Apollo 324 System and accelerate the company’s responsiveness to the NGS community. “The Business Unit structure enables us to leverage the increasing market acceptance of the Apollo 324 System and our expertise in nucleic acid chemistry automation to continue leading the marketplace,” explained Stevan Jovanovich, Ph.D., President and Chief Executive Officer of IntegenX.

Regarding the new product introduction, Sequencing Business Unit Vice President Tom Olenic said, “With our expanding range of kits optimized for the Apollo 324 System, we’re proving that researchers and clinicians can take advantage of fast, automated protocols for DNA sequencing, RNA-Seq, and ChIP-Seq applications without the frustration and inefficiencies of programming a robotic system. The Apollo 324 instrument finally makes it practical to prepare samples for studies on biopsy samples in the process of solving biological problems,” added Mr. Olenic.

 

About IntegenX Inc.

IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented reagents for DNA and RNA preservation including GenTegra® for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples. For more information, please visit www.integenx.com.  

 

IntegenX, the IntegenX logo, Apollo 324, PrepX, GenTegra and GenPlate are trademarks of IntegenX Inc. All other names and trademarks are the property of their respective owners.

 

Contact:

Howard D. Goldstein
IntegenX Inc.
5720 Stoneridge Drive, Suite 300
Pleasanton, CA 94588

925.701.3481

howardg@integenX.com

 

###

IntegenX Announces U.S. Launch of the RapidHIT™ 200 System – Rapid DNA Technology That Will Revolutionize the Use of DNA in Law Enforcement and Forensics

Future of DNA Forensics Demonstrated at International Police Chief Meeting – A New Partnership Between Crime Labs and Police Now Possible

SAN DIEGO and PLEASANTON, Calif. – October 1, 2012 – IntegenX Inc., a leading developer of rapid human DNA identification technology, today announced the commercial availability of its RapidHIT 200 Human DNA Identification System in the U.S. at the 2012 International Association of Chiefs of Police Conference and Exposition in San Diego, California. Representatives from IntegenX are on site at the meeting to demonstrate the self-contained desktop system, which is the first commercially available rapid DNA device.

Rapid DNA analysis is a transformative technology that promises to fundamentally change the way investigations are conducted by enabling law enforcement personnel to quickly and definitively link a suspect’s DNA to a crime scene, or eliminate suspicion, all while the suspect is still in police custody.

The RapidHIT 200 System provides actionable intelligence by automating and accelerating the process of producing standardized DNA profiles from cheek swabs in about 90 minutes. This is compared to a process that currently takes up to eight instruments and at least a day in a specialized lab, with results typically returned to police in weeks to months.

Stevan Jovanovich, President and Chief Executive Officer of IntegenX commented: “The availability of this technology now will revolutionize the use of DNA in law enforcement. We see the implementation of rapid DNA as reinforcing the partnership between crime labs and police – putting more power in their hands to get DNA results faster. Law enforcement agencies have been waiting a long time for this capability. We are proud to be the first to deliver it and to say “Rapid DNA is here!”

Numerous international law enforcement and security agencies use DNA-based human identification to make informed decisions regarding the arrest, detention or release of suspects, as well as to analyze crime scene evidence. By integrating what was until now a multi-step, multi-system process, rapid DNA technology has the potential to accelerate and expand the use of proven DNA technologies to help the efforts of law enforcement, homeland security, and defense to create safer communities and a safer world.

One of the first police departments to place an order for the RapidHIT 200 System is Palm Bay, Florida, an organization known for its progressive use of DNA to solve high volume crimes.

“We are extremely proud of what we have been able to accomplish so far using DNA, and expect the RapidHIT 200 System to greatly accelerate our efforts,” said Doug Muldoon, Police Chief of Palm Bay. “Based on our experience, the more we can use this ultimate identification tool in our work, the more our crime rates go down and our case closure rates go up. That is good news for creating safer communities for our citizens.  Rapid DNA will enhance our methods for dealing with high volume crimes using our locally created database.”

“This is one of the best crime fighting tools we have seen in decades. It allows law enforcement to identify the bad guys and put them in jail. It also protects the innocent from going to jail for a crime they did not commit,” added Chief Muldoon.

Dr. Jovanovich will speak along with Chief Muldoon and the Denver District Attorney, Mitch Morrissey, during a press conference today at the IACP meeting at 9:00 a.m. PT. For more information about IACP, please visit: www.theiacpconference.org.

In celebration of this historic milestone in forensics, IntegenX has produced a short video that features leaders in law enforcement discussing the impact of rapid DNA in crime fighting.  The video is available for download and distribution at http://integenx.com/video-rapid-dna-with-the-integenx-rapidhit-200/.

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, proprietary PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented reagents for DNA and RNA preservation including GenTegra® for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

###

 

 

Media Contact:

Maurissa Messier
For IntegenX
+1 760-539-7417
maurissa@bioscribe.com

IntegenX Launches First RapidHIT™ Human DNA Identification System at EAFS 2012

First Rapid DNA Instruments Shipping This Month

PLEASANTON, Calif., USA and THE HAGUE, THE NETHERLANDS – August 20, 2012 – IntegenX Inc., a leading developer of rapid human DNA identification technology, today launched its RapidHIT™ Human DNA Identification System to the European law enforcement and forensic communities at the 6th European Academy of Forensic Science (EAFS 2012) Conference in The Hague, The Netherlands.  Representatives from IntegenX are on site at the meeting to demonstrate the self-contained desktop system and share data produced by its first users.

The RapidHIT System automates and accelerates the process of producing standardized DNA profiles from cheek swabs and other human samples in about 90 minutes.  Rapid DNA analysis is a transformative technology that promises to fundamentally change the way investigations are conducted by enabling law enforcement personnel to quickly and definitively link suspects to crimes while they are still in custody.

“We have spent a great deal of time working closely with the law enforcement, forensic and judicial communities to understand their needs and priorities for DNA-based human identification, and are now confident that we are the partner of choice to help the international community to successfully deploy this important advance in crime solving,” said Stevan Jovanovich, President and Chief Executive Officer of IntegenX.  “This is a very exciting time as we introduce the world’s first rapid DNA analysis system to the professionals who will be on the cutting edge of implementing it to identify offenders, clear innocent suspects quickly, and prevent future crimes.”

Numerous international law enforcement and security agencies use DNA-based human identification to make informed decisions regarding the arrest, detention or release of suspects, as well as to analyze crime scene evidence.  By integrating a multi-step, multi-system process, rapid DNA technology has the potential to accelerate and expand the use of proven DNA technologies to help the efforts of law enforcement, homeland security, and defense to create safer communities.

The RapidHIT System will be on display at EAFS in exhibit space #58.  Technical marketing manager Keith Elliott will describe the instrument and early data from users in “Real-time DNA Using the RapidHIT 200,″ Tuesday, August 21 at 11:00 AM, and IntegenX will contribute additional information at the “Mobile DNA Technologies” workshop on Wednesday, August 22 at 9:30 AM.

IntegenX will begin shipping early access RapidHIT systems this month.  The company will launch the system to the U.S. market at the 119th Annual International Association of Chiefs of Police Conference and Law Enforcement Education and Technology Exposition in San Diego, California, September 29 – October 3, 2012.

In celebration of this historic milestone in forensics, IntegenX has produced a short video that features leaders in law enforcement discussing the impact of rapid DNA in crime fighting.  The video is available for download and distribution at http://integenx.com/video-rapid-dna-with-the-integenx-rapidhit-200/.

About IntegenX Inc.

IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products.  IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications.  The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented reagents for DNA and RNA preservation including GenTegra™ for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples.  For more information, please visit www.integenx.com.

 

IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

 

###

 

Media Contact:

Maurissa Messier
For IntegenX
+1 760-539-7417
maurissa@bioscribe.com

IntegenX Unveils RapidHIT™ Human Identification System to U.K. Forensic Community

First Rapid DNA Instruments Shipping this Summer

PLEASANTON, Calif., USA and WARRINGTON, UK – June 27, 2012 – IntegenX Inc., a privately held company and leading developer of rapid human DNA identification technology, DNA sequencing library preparation systems, and DNA/RNA room temperature stability and storage products, today announced the unveiling of its RapidHIT™ Human Identification System at the new Key Forensic Services Ltd (KFS) facility in Warrington, United Kingdom.  KFS is one of the early access sites for the new system and will be the first to provide Rapid DNA identification capabilities to U.K. law enforcement organizations.

Rapid DNA analysis is a transformative technology that promises to fundamentally change the way investigations are conducted by enabling law enforcement personnel to quickly and definitively identify suspects while they are still in custody.  Numerous international law enforcement and security agencies around the world use DNA-based human identification to make informed identification decisions regarding the arrest, detention, or release of suspects, as well as to analyze crime scene evidence.  Rapid DNA technology has the potential to help create safer communities through its many applications from policing to homeland security and defense.

“The RapidHIT System will revolutionize the provision of DNA profiles, and we are honored to be one of the first forensic laboratories in the world to deploy it,” said Paul Hackett, KFS Group Managing Director.  “We look forward to delivering unprecedented improvements in turnaround times for our U.K. law enforcement customers with this system in our expanded state-of-the-art facility.”

“The RapidHIT system will allow, for the first time, rapid DNA analysis at the point of collection, setting a new standard in the usage of DNA profiles as an actionable biometric similar to fingerprints,” added Stevan Jovanovich, President and Chief Executive Officer of IntegenX.  “KFS is among the world’s leading forensic science providers and we are pleased to be working with them on the introduction of our Rapid DNA technology to the U.K.  Their feedback will be invaluable as we prepare for the global commercial launch of the RapidHIT system later this summer.”

The IntegenX RapidHIT 200 is a mobile, self-contained Human Identification (HID) system that automates and accelerates the process of producing standardized DNA profiles from buccal swabs and other human samples in less than 90 minutes.  The RapidHIT system produces human DNA profiles compatible with the U.K. National DNA Database (NDNAD).

In celebration of this historic milestone in forensics, IntegenX has produced a short video that features leaders in law enforcement discussing the impact of rapid DNA in crime fighting. The video is available for download and distribution at http://integenx.com/video-rapid-dna-with-the-integenx-rapidhit-200/.

About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, Next-Gen Sequencing library preparation systems, and DNA/RNA ambient temperature stability and storage products.  IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications.  The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented DNA and RNA reagents including GenTegra™ for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples.  For more information, please visit www.integenx.com.

About Key Forensic Services Ltd.
Key Forensic Services Ltd. (KFS) is a privately-held UK based company that delivers forensic science solutions to the criminal justice system and private sector clients in the United Kingdom and Internationally.  Its traditional forensic services include search and recovery of submissions for DNA profiling; document examinations; footwear marks screening; determination of weight, identification, and purity of drugs, as well as examination of items recovered from a crime scene for drug traces; forensic firearms training and awareness; gunshot residue examination; and evaluation and reporting of fingerprint casework.  The company also offers digital forensic services, such as mobile phone examination, hex dumping, cell site analysis, computer forensics, forensic video analysis, and forensic audio services; and supplies forensic kits and packaging supplies.  In addition, it provides professional forensic consultancy services for criminal defense lawyers; specialist custom collection and delivery service to police forces; and training and consultancy services.  For more information, please visit www.keyforensic.co.uk.

IntegenX, the IntegenX logo, and RapidHIT are trademarks of IntegenX Inc. All other names or trademarks are the property of their respective owners.

###

Media Contacts:

Maurissa Messier
For IntegenX
+1 760-539-7417
maurissa@bioscribe.com

Paul Whitehouse
For Key Forensic Services Ltd
+44 (0) 2476 323393
paul.whitehouse@keyforensic.co.uk

FBI Lab Veteran Dr. Joseph A. DiZinno to Lead IntegenX New D.C. Office as Senior Director of Federal Programs

PLEASANTON, CA – June 18, 2012 – IntegenX Inc., a privately held company and leading developer of rapid human DNA identification technology, today announced the opening of its Washington, D.C.-area office to support the company’s work with federal agencies. The office will be managed by Dr. Joe DiZinno, who has been appointed Senior Director of Federal Programs for IntegenX.

“We are pleased to announce the opening of our D.C. office, which will provide a strategic base of operations to engage with the many U.S. government agencies and organizations based in the region,” said Stevan Jovanovich, Ph.D., President and Chief Executive Officer of IntegenX. “Joe’s leadership and extensive expertise in working within this community will be instrumental as we gear up for the commercial launch of our RapidHIT™ system and deepen our collaborations with federal agencies interested in tapping into the power of rapid DNA technology.”

Dr. DiZinno joins IntegenX from BAE Systems where he was Technical Director, Homeland Security and Law Enforcement in Washington, D.C. Prior to BAE, Joe spent 22 years with the Federal Bureau of Investigation (FBI), starting his career as a Special Agent and retiring in 2008 as Director of the FBI Laboratory. In this role, he oversaw all case-working and response units related to domestic and international criminal and terrorist cases and led a team of 550 professionals providing forensic examinations, technical support, expert witness testimony, and training to federal, state, and local law enforcement agencies. His professional affiliations include former Vice Chairman of the Council of Federal Forensic Laboratory Directors, Chairman of the mtDNA group of The Scientific Working Group on DNA Analysis Methods and member of the American Academy of Forensic Science. He currently serves as an adjunct faculty member at George Mason University where he instructs undergraduate and graduate students in forensic science. Dr. DiZinno is a graduate of the University of Notre Dame and The Ohio State University College of Dentistry.

“Much of my work with the FBI focused on the development and application of new forensic techniques that expanded the capabilities of law enforcement to identify criminals and clear the innocent,” said Dr. DiZinno. “The RapidHIT system is a truly game-changing technology that is poised to become the new de facto standard in DNA-based forensics. It’s an exciting time to join IntegenX and establish the company’s presence in the nation’s capital.”

The IntegenX RapidHIT 200 is a self-contained Human Identification (HID) system that automates and accelerates the process of producing standardized DNA profiles from mouth swabs and other human samples in less than 90 minutes. Numerous local, state, national, and international law enforcement and security agencies use DNA-based human identification to make informed identification decisions regarding the arrest, detention, or release of suspects, as well as to analyze crime scene evidence. The RapidHIT 200 system will allow, for the first time, rapid DNA analysis at the point of collection—such as on arrest or detention—setting a new standard in the usage of DNA profiles as an actionable biometric similar to fingerprints.

IntegenX™ Names Biotechnology Veteran David V. Smith Chief Operating Officer

PLEASANTON, CA – May 15, 2012 –IntegenX Inc., a privately held company and leading developer of rapid human DNA identification technology, DNA sequencing library preparation systems, and DNA/RNA room temperature stability and storage products, today announced the appointment of David V. Smith as Chief Operating Officer.

David V. Smith has more than 30 years of financial and operational management experience, and has held leadership positions in the biotechnology industry for more than two decades. Most recently, he was Executive Vice President and Chief Financial Officer of Thoratec Corporation. Prior to joining Thoratec in 2006, Mr. Smith served as Vice President and Chief Financial Officer of Chiron Corporation, a company he joined in 1999. At Chiron, he held a number of increasingly responsible positions including Vice President, Principal Accounting Officer and Controller, and Vice President of Finance. Prior to Chiron, Mr. Smith served as the Vice President of Finance and Chief Financial Officer at Anergen Incorporated from 1997 to 1999. From 1988 to 1997, Mr. Smith served in various financial management positions with Genentech, Inc., both in the United States and Europe. He previously held finance positions at Syntex Corporation and IBM Corporation.

“Of all the advances in life science technology, the integration of complex chemistry and biology systems is now made possible by the practical utilization of microfluidics technology. The resulting sample-to-answer solutions are revolutionizing medical care, medical discovery and other applications that affect our health and safety,” said Mr. Smith. “I am particularly excited to join IntegenX just as the company prepares to launch the first microfluidics-based rapid DNA human identification system for the law enforcement, defense, forensics and security markets.”

Mr. Smith is currently chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc. and was previously chair of the Audit Committee and a Director of Perlegen Sciences, Inc. He holds a B.A. in Economics and History from Willamette University and an M.B.A. specializing in finance from Golden Gate University.

Dr. Stevan Jovanovich, Chief Executive Officer of IntegenX commented: “David has been part of the executive leadership and management of the biotechnology industry since its inception in the 1980s, including working within large public companies operating in highly regulated markets. Having played a key role in pioneering companies such as Genentech, Chiron, and Thoratec, we are proud to have him join us at this exciting phase of growth at IntegenX as we lead the establishment of the emerging rapid DNA identification industry.”